TearScience® is uniquely positioned to improve on results for dry eye sufferers and acquire a significant share in the dry eye disease category.
With $650 million under management, DeNovo invests in medical devices and biotechnology companies.
Since 1985, Essex Woodlands has raised seven additional funds with nearly $2.5 billion under management, making them one of the world’s largest and most established healthcare venture capital firms.
Funds breakthrough ventures and backs exceptional entrepreneurs via capital, business building resources, and strategic support.
IGC is an independent venture capital firm specializing in expansion-stage investments in technology and healthcare.
Since its founding in 2002, Quaker has invested in dozens of innovative, high impact healthcare companies. Quaker manages over $700 million in committed capital and is currently investing its second fund.
A venture capital firm that focuses exclusively on contributing capital and expertise to emerging healthcare technology companies.